Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required) | PAR 21 211

Frequently Asked Questions (FAQs)

1) What is this funding opportunity?

This opportunity is the National Institute of Mental Health (NIMH) Funding Opportunity Announcement (FOA) titled "Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)" (PAR-21-211; reissue of PAR-18-431). It supports pilot-stage effectiveness clinical trials focused on the post-acute phase of mental health conditions.

2) Which NIH institute is offering this grant?

The opportunity is offered by the National Institute of Mental Health (NIMH), within the National Institutes of Health (NIH).

3) What mechanism does this FOA use?

This FOA uses the NIH R34 mechanism, and a clinical trial is required under the announcement.

4) What does "Clinical Trial Required" mean for applicants?

Based on the information provided, applicants should be prepared to propose and describe a clinical trial, including the trial design, outcomes, safety monitoring, and how feasibility and acceptability will be measured.

5) What phase of care is the FOA focused on?

The FOA focuses on the post-acute phase of mental health conditions, meaning the period after an initial or acute course of care when people may have improved but still experience residual symptoms, functional impairment, relapse risk, or challenges staying engaged in appropriate services.

6) What is the main goal of an R34 project under this FOA?

The goal is to conduct a rigorous pilot effectiveness trial that generates practical, real-world evidence needed to justify and shape a later, fully powered effectiveness trial. The expectation is not to run a definitive, large-scale study at the R34 stage.

7) What kinds of research questions should the pilot trial answer?

The pilot trial is intended to answer early, practical questions such as whether the intervention can be implemented as planned, whether participants will enroll and remain engaged, whether the approach is acceptable and tolerable, whether there are safety issues, and whether there are preliminary signals of improved outcomes.

8) What outcomes or planning parameters is the FOA looking for?

The FOA emphasizes producing operational details and estimates needed to design a later effectiveness study, including (as described) recruitment rates, adherence, retention, implementation fidelity, outcome variability, and other planning parameters.

9) What does it mean that interventions should be "thoughtfully matched to the stage of illness"?

It means the intervention should fit the realities of the post-acute period in both what it targets (for example, maintaining gains from earlier treatment, preventing relapse, improving adherence, supporting recovery and functioning, and promoting appropriate service use) and the intensity or burden it places on patients, families, clinicians, and systems.

10) What types of interventions are in scope?

The scope includes both therapeutic interventions and service delivery models intended to improve longer-term outcomes after the acute phase of treatment.

11) Can you give examples of approaches that fit this FOA?

Examples mentioned include structured relapse-prevention supports, stepped-care or maintenance strategies, care coordination approaches, adherence and engagement supports, technology-assisted follow-up, strategies to manage residual symptoms, and models that help people use the right level of care at the right time.

12) Does the FOA require the intervention to be realistic for real-world settings?

Yes. The description emphasizes that the intervention should be realistic for the settings and populations in which it is intended to be used.

13) What is the emphasis on "targets" or "mechanisms" in this FOA?

A major emphasis is demonstrating that the intervention engages the presumed targets or mechanisms believed to drive clinical benefit, not just that it can be delivered.

14) Is this FOA meant to fund a definitive effectiveness trial?

No. This FOA draws a clear boundary between pilot work and definitive effectiveness testing. It supports early effectiveness research meant to inform and de-risk a larger study rather than answering the final effectiveness question on its own.

15) What comes after an R34 pilot project if results are promising?

The described pathway is that fully powered, definitive effectiveness trials for post-acute phase interventions are expected to be pursued through a separate R01 pathway (noted as TEMP-11234 in the description). The R34 is intended to build evidence and operational know-how to make an R01-scale trial feasible and well-designed.

16) Who is eligible to apply?

Eligible applicants are broad and include many organization types that can carry out clinical research and partner with service systems. Domestic eligibility includes state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing and Indian housing authorities; nonprofits with and without 501(c)(3) status (when not an institution of higher education); for-profit organizations (other than small businesses); and small businesses.

17) Are non-U.S. (foreign) organizations eligible?

Yes. The information provided explicitly lists non-U.S. entities (foreign organizations) among the eligible groups highlighted in the announcement.

18) Are minority-serving institutions and community-based organizations encouraged or eligible?

The announcement highlights additional eligible groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), and faith-based or community-based organizations, reflecting an intent to encourage diverse institutional participation and research settings.

19) What is the funding instrument and program type?

The funding instrument is a grant under a discretionary program, and the funding activity category is health-related.

20) What is the CFDA number listed for this opportunity?

The CFDA number listed is 93.242.

21) When was this opportunity created and what is the listed closing date?

The opportunity was created on April 1, 2021, and the listed original closing date is January 25, 2025.

22) Does the public description provide an award ceiling or the expected number of awards?

No. The public description does not specify an award ceiling or the expected number of awards in the provided fields.

23) Where should applicants look for budget structure and project period expectations?

The information provided indicates applicants would typically confirm budget structure, project period expectations, and any institute-specific limits in the full FOA and related NIH policy guidance.

24) What should applicants be ready to include regarding feasibility and acceptability?

Applicants should be ready to explain how feasibility and acceptability will be measured, including whether participants will enroll and stay involved, whether the approach is acceptable and tolerable, and whether the intervention can be implemented as planned.

25) What should applicants be ready to include regarding safety?

Applicants should be ready to describe safety monitoring and to assess whether there are any safety issues during the pilot effectiveness trial.

26) What is meant by "post-acute interventions and services" in this context?

In this FOA, post-acute interventions and services refer to therapeutic and service delivery approaches delivered after the acute course of care, aimed at maintaining gains, preventing relapse, addressing residual symptoms, improving functioning, supporting adherence and engagement, and promoting appropriate ongoing service use.